![Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial | Trials | Full Text Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial | Trials | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13063-020-04637-z/MediaObjects/13063_2020_4637_Fig1_HTML.png)
Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial | Trials | Full Text
![PDF] Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. | Semantic Scholar PDF] Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/814ad6ccbfa9defca4d2b00c4672f9070cf6b8da/16-Figure1-1.png)
PDF] Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. | Semantic Scholar
![A Randomized, Open-Label Trial of Hen's Egg Oral Immunotherapy: Efficacy and Humoral Immune Responses in 50 Children - The Journal of Allergy and Clinical Immunology: In Practice A Randomized, Open-Label Trial of Hen's Egg Oral Immunotherapy: Efficacy and Humoral Immune Responses in 50 Children - The Journal of Allergy and Clinical Immunology: In Practice](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d7112a08-bd35-4385-a6a4-8e7901912c1d/gr1.jpg)
A Randomized, Open-Label Trial of Hen's Egg Oral Immunotherapy: Efficacy and Humoral Immune Responses in 50 Children - The Journal of Allergy and Clinical Immunology: In Practice
PLOS ONE: A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
![Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – An open-label trial - Seizure - European Journal of Epilepsy Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – An open-label trial - Seizure - European Journal of Epilepsy](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f5b9964c-4331-4321-a712-8d6a65155a91/gr1_lrg.jpg)
Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – An open-label trial - Seizure - European Journal of Epilepsy
![Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol](https://bmjopen.bmj.com/content/bmjopen/3/7/e002902/F1.large.jpg)
Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol
![Understanding Clinical Trial Terminology: What is an Open Label Clinical Trial? - Concert Pharmaceuticals Understanding Clinical Trial Terminology: What is an Open Label Clinical Trial? - Concert Pharmaceuticals](https://www.concertpharma.com/wp-content/uploads/2019/06/clinicaltrials-2-e1566478031946.jpg)
Understanding Clinical Trial Terminology: What is an Open Label Clinical Trial? - Concert Pharmaceuticals
![Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial - The Lancet Neurology Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/e53ef392-4fec-49e2-b653-2896383e183d/gr1.gif)
Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial - The Lancet Neurology
![An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19 - eClinicalMedicine An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19 - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2f77f968-1e6c-49f4-9f56-a42b48f4fb05/gr1.jpg)
An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19 - eClinicalMedicine
![Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition - Journal of Clinical Epidemiology Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition - Journal of Clinical Epidemiology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2080812205/2072208225/gr1.jpg)
Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition - Journal of Clinical Epidemiology
![ASCO GU 2020: Results from ATLAS, a Phase 2, Open-Label Trial: Rucaparib for Recurrent, Locally Advanced or Metastatic Urothelial Carcinoma ASCO GU 2020: Results from ATLAS, a Phase 2, Open-Label Trial: Rucaparib for Recurrent, Locally Advanced or Metastatic Urothelial Carcinoma](https://www.urotoday.com/images/atlas_trial_schema.png)
ASCO GU 2020: Results from ATLAS, a Phase 2, Open-Label Trial: Rucaparib for Recurrent, Locally Advanced or Metastatic Urothelial Carcinoma
![An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 - Clinical Microbiology and Infection An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 - Clinical Microbiology and Infection](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7b2838e8-53f2-4a1b-9a19-5738831c53bd/gr1.jpg)